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Abstract
Introduction: Antifibrinolytic agents are commonly used during cardiac surgery to minimize bleeding. Because of
safety concerns, aprotinin was withdrawn from the market in 2007. Since then, tranexamic acid (TXA) has become
the antifibrinolytic treatment of choice in many heart centers. The safety profile of TXA has not been extensively
studied. Therefore, the aim of this study was to evaluate safety and efficiency of TXA compared with aprotinin in
cardiac surgery.
Methods: Since July 1, 2006, TXA has been administered at a dose of 50 mg/kg tranexamic acid before
cardiopulmonary bypass (CPB) and 50 mg/kg into the priming fluid of the CPB. Prior to this, all patients were
treated with aprotinin at a dose of 50,000 KIU per kilogram body weight. Safety was evaluated with mortality,
biomarkers, and the diagnosis of myocardial infarction, ischemic stroke, convulsive seizures, and acute renal failure
in the intensive care unit (ICU), intermediate care unit (IMCU), and hospital stay. Efficiency was evaluated by the
need for transfusion of blood products and total postoperative blood loss.
Results: After informed consent, 893 patients were included in our database (557 consecutive patients receiving
aprotinin and 336 patients receiving TXA). A subgroup of 320 patients undergoing open-heart procedures (105
receiving TXA and 215 receiving aprotinin) was analyzed separately. In the aprotinin group, a higher rate of late
events of ischemic stroke (3.4% versus 0.9%; P = 0.02) and neurologic disability (5.8% versus 2.4%; P = 0.02) was
found. The rate of postoperative convulsive seizures was increased in tendency in patients receiving TXA (2.7%
versus 0.9%; P = 0.05). The use of TXA was associated with higher cumulative drainage losses (PANOVA < 0.01; Ptime
< 0.01) and a higher rate of repeated thoracotomy for bleeding (6.9% versus 2.4%; P < 0.01). In the subgroup of
patients with open-chamber procedures, mortality was higher in the TXA group (16.2% TXA versus 7.5% aprotinin;
P = 0.02). Multivariate logistic regression identified EURO score II and CPB time as additional risk factors for this
increased mortality.
Conclusions: The use of high-dose TXA is questioned, as our data suggest an association between higher
mortality and minor efficiency while the safety profile of this drug is not consistently improved. Further
confirmatory prospective studies evaluating the efficacy and safety profile of TXA are urgently needed to find a
safe dosage for this antifibrinolytic drug.
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Antifibrinolytic agents are commonly used during car-
diac surgery to minimize bleeding and to reduce expo-
sure to blood products. In 2006, the use of aprotinin
became controversial when the drug was associated with
an increased risk of renal failure, myocardial infarction,
stroke, and death in a large observational study [1]. Ret-
rospective analyzed data from the Mc SPI database pub-
lished by Mangano et al. [ 1 , 2 ]s e e m e dt os h o wt h a tt h e
use of aprotinin was associated with the increased risk
of postoperative complications after cardiac surgery and
even with an increased mortality. The authors of this
study concluded that the association between aprotinin
and serious end-organ damage indicates that its contin-
ued use is not prudent [1]. In contrast, the less-expen-
sive generic medications ε-aminocaproic acid and
tranexamic acid (TXA) would be safe alternatives. How-
ever, this conclusion might be problematic, being drawn
for all types of cardiac surgical patients from a retro-
spective study. However, subsequent published cohort
studies also linked aprotinin to an increased risk of mor-
bidity and mortality [2-5].
In 2007, data from the BART trial were published [6].
The BART trial originally was designed as a multicenter
trial looking into whether aprotinin was superior to TXA
and aminocaproic acid in decreasing the risk of massive
postoperative bleeding in patients undergoing high-risk
cardiac surgery. The trial was terminated early because of
a higher rate of death in patients receiving aprotinin [6].
Since aprotinin has been withdrawn from the market in
many countries, TXA has become the routine antifibri-
nolytic therapy of choice. Recently, however, evidence
indicated that the application of TXA might be asso-
ciated with morbidity as well. Noteworthy are especially
neurologic complications that have been shown by recent
studies, especially in pediatric patients and in patients
undergoing open-heart procedures [7-9]. From this point
of view, it is crucial to know the safety profile of different
antifibrinolytic therapies in cardiac surgery to prevent
any harm in patients at risk. This is especially important
in the context of the work of Karkouti [10], showing that
from their single-center experience, high-risk patients
given TXA had an excessive complication rate.
Therefore, the aim of this prospective observatory
study was to evaluate the safety and efficiency profile of
TXA compared with aprotinin in patients undergoing
cardiac surgery with CPB and in patients with open-
heart procedures, as was suggested recently [7].
Materials and methods
Group assignment
After publication of the first Mangano article raising con-
cerns about the safety profile of aprotinin, we changed
our routine administration of antifibrinolytics. On July 1,
2006, we discontinued the use of aprotinin. From that
time, we prospectively collected anonymized data in a
database evaluating parameters of efficiency and safety.
Data of 336 patients receiving TXA were compared with
retrospectively collected data from 557 consecutive
patients receiving aprotinin undergoing cardiac surgery
with cardiopulmonary bypass (CPB) during the 6 months
before the change in our antifibrinolytic practice. Patients
gave consent for observational studies in our institution.
The local ethics committee approved this observational
study. A subgroup of 320 patients undergoing open-heart
procedures (105 receiving TXA and 215 receiving aproti-
nin) was analyzed separately (Figure 1).
Anesthetic, cardiopulmonary bypass, and intensive care
management
Our standard anesthetic practice for patients undergoing
cardiac surgery with CPB is to use etomidate, sufentanil,
and pancuronium for induction and sevoflurane, with
propofol and sufentanil infusion for maintenance. In all
patients, a radial artery was punctured before induction.
The radial artery catheter was used for measurement of
arterial blood pressure and to obtain blood samples for
point-of-care blood gas analysis (ABL-700 series; Radio-
meter, Copenhagen, Denmark). A central venous cathe-
ter was inserted via the right internal jugular vein.
The prime for the cardiopulmonary bypass circuit
consisted of 600 ml of crystalloid fluid, 500 ml of 6%
hydroxyethylstarch (HES) solution (Voluven; Fresenius-
Kabi, Bad Homburg, Germany). A total dose of 50,000
KIU aprotinin per kilogram bodyweight was adminis-
tered during CPB in the aprotinin group. The TXA
group received 50 mg/kg bodyweight as a bolus before
CPB and 50 mg/kg bodyweight into the CPB circuit.
Pump flow was adjusted to maintain a mean arterial
pressure (MAP) of 55 to 60 mm Hg and a venous oxy-
gen saturation >75% during CPB. When the MAP could
not be maintained by adjusting the pump flow, norepi-
nephrine was used. During cardiopulmonary bypass, a
partial arterial pressure of oxygen (paO2)o f1 5 0t o
250 mm Hg was maintained. Body temperature was
kept between 35.5 and 36.0°C during CPB, and intermit-
tent antegrade warm-blood cardioplegia was used as
described by Calafiore [11]. After surgery, all patients
were transferred to the ICU. ICU management and
transfusion practice did not differ between patients of
both groups. After ICU treatment, all patients were first
transferred to the intermediate care unit (IMCU).
Database management
The prospective data collection begun on July 1, 2006,
when the first patient received routinely TXA for
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ating procedures. Into the same database, we retrospec-
tively collected consecutive data from the last 6 months
from patients receiving aprotinin for cardiac surgery
with CPB (beginning from January 2 until June 30,
2006).
Safety was evaluated by routinely monitored myocar-
dial biomarkers (creatinine kinase (CK) and isoenzyme
MB (CK-MB), creatinine, and the diagnosis of myocar-
dial infarction, ischemic stroke, intracerebral hemor-
rhage, convulsive seizures, and acute renal failure during
ICU and IMCU stay. Efficiency was documented in this
database by the need for transfusion of blood products
(erythrocyte concentrates, fresh frozen plasma, and pla-
telet concentrates) and total postoperative blood loss
(first 6 h after surgery, 24 h after surgery, until 48 hours
after surgery), as well as the number of surgical reex-
plorations for bleeding. We documented in-hospital
mortality, duration of ventilation, ICU treatment, and
hospital stay as further outcome parameters. All compli-
cations were graded as early (during ICU stay) and late
(during further hospital stay). Transfusion was guided
by our written and published local standard operating
procedures.
The diagnosis of myocardial infarction was based on
t h ep r e s e n c eo fn e wQw a v e sin two contiguous elec-
trocardiogram leads and an increase of myocardial
creatine kinase (CK-MB) above 10% of total creatine
kinase (CK) or confirmed graft occlusion within the
first 30 days after surgery. Ischemic stroke was defined
as a focal neurologic deficit lasting more than 24 h
and had to be confirmed by a cerebral CT scan and
the attending neurologic consultant. Neurologic dis-
ability was defined as any newly developed neurologic
impairment that lasted longer than 24 h and had to be
confirmed by a neurologic consultant. Convulsive sei-
zures were defined as clinically apparent seizures. All
patients with seizures underwent routine cerebral CT
scan to exclude ischemia or bleeding. Acute renal fail-
ure was defined as a decrease in urine output below
500 ml/24 h, the need for at least one dialysis treat-
ment, a doubling of the baseline serum creatinine
level, or a postoperative serum creatinine level of more
than 150 μmol/L (1.7 mg/dl) with normal creatinine
before surgery. Thrombembolic cause of death was
defined as death due to a thromboembolic event (for
example, myocardial infarction, ischemic stroke, pul-
monary embolism).
Figure 1 CONSORT Flow chart of the study design.
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dures was defined as valve surgery, CABG with atrial
ablation procedures on the ascending aorta, ventriculot-
omy, and atrial and ventricular septal defect repair.
Statistical methods
Results were expressed as mean ± standard deviation
(SD) in case of continuous variables. Absolute and rela-
tive frequencies were used for categoric and dichoto-
mous variables. The effect on outcome variables was
analyzed by using the Exact c
2 test for categoric and
dichotomous variables. A check for normal distribution
did not reveal substantial deviations from normality (Lil-
liefors test); therefore, we applied the t test for compari-
sons of independent groups in case of continuous
variables.
Multivariate backward stepwise logistic regression ana-
lysis with mortality as the response was accomplished to
investigate the impact of interesting clinical characteris-
tics such as age, CPB time, Euro II Score, type of sur-
gery, creatinine, hemoglobin, and type of antifibrinolytic.
Odds ratios (ORs) with 95% confidence intervals (CIs)
and the corresponding P values were determined.
Changes in blood loss over time were analyzed by using
nonparametric analysis of longitudinal data in a two-fac-
torial design (first factor: TXA vs. aprotinin; second fac-
tor: Time). Therefore, we compared all the time points
simultaneously on the corresponding response curves.
The P values for differences between groups (first
factor) were marked with Pgroups, for changes in time
(second factor) with Ptime, and for interactions (differ-
ences increase with time) with Pintact.
As this study was designed as an exploratory investiga-
tion, no statistical sample size (power) calculation was
conducted.
A P value < 0.05 (two-sided) was considered statisti-
cally significant. Multiple testing for differences between
the groups in question was regarded as exploratory and
not confirmatory; therefore, no adjustments for multipli-
city were made. Confirmatory studies should use data
from this study for the design of an adequately powered
trial confirming our results.
Statistical analysis was carried out by using the Soft-
ware Package for Social Sciences, 16.0 SPSS® for Macin-
tosh (SPSS, Inc., Chicago, IL).
Results
During the 12-month study period, we included 893
patients undergoing cardiac surgery with CPB into our
database, with a group of 557 consecutive patients
receiving aprotinin and 336 patients receiving TXA
(Figure 1).
Patient’s baseline characteristics are shown in Table 1.
No significant differences were found with regard to
baseline characteristics, with the exception of preoperative
hemoglobin being significantly lower in patients in the
TXA group (13.1 mg/dL ± 2.0 versus 13.6 mg/dL ± 1.8; P
< 0.01). In Table 2, types of surgery are displayed. Surgery-
type related data (Table 2) did not differ between groups
(P = 0.15). Also the EUROSCORE II did not differ (6.3 ±
3.9 aprotinin group versus 5.8 ± 3.7 TXA group; P = 0.08).
Furthermore, no significant differences were noted
between both groups with regard to comorbidities as dia-
betes mellitus (P = 0.71), peripheral vascular disease (P =
0.76), renal insufficiency (P = 0.10), and COPD (P = 0.47).
No significant difference existed between both groups
concerning the treatment with and, if treated, how many
Table 1 Baseline characteristics of the patients in the
aprotinin and tranexamic acid groups
Aprotinin Tranexamic acid
Mean SD Mean SD P
Age (years)
All patients 68 11 67 11 0.09
Open-heart procedures 69 11 68 13 0.25
Height (cm)
All patients 171 9 172 9 0.88
Open-heart procedures 171 9 170 11 0.71
Weight (kg)
All patients 80 15 80 16 0.74
Open-heart procedures 77 17 77 15 0.94
Ejection fraction preop (%)
All patients 55 15 53 15 0.20
Open-heart procedures 53 14 51 16 0.18
Creatinine preop (mg/dL)
All patients 1.18 0.76 1.24 0.87 0.28
Open-heart procedures 1.14 0.46 1.31 1.03 0.04
Platelets preop (/nL)
All patients 235 88 239 80 0.51
Open-heart procedures 241 86 241 88 0.97
WBC preop (/nL)
All patients 8.3 4.2 8.1 2.9 0.37
Open-heart procedures 8.4 4.2 8.1 3.5 0.55
Hemoglobin preop (mg/dL)
All patients 13.6 1.8 13.1 2.0 < 0.01
Open-heart procedures 13.2 1.9 12.5 1.8 < 0.01
Prothrombin time preop (%)
All patients 93 15 93 14 0.69
Open-heart procedures 91 17 88 16 0.15
PTT preop (s)
All patients 41.1 23.7 42.3 24.0 0.49
Open-heart procedures 40.6 22.2 41.3 17.8 0.76
AT III preop (%)
All patients 97 15 95 17 0.17
Open-heart procedures 97 14 93 19 0.05
AT III, antithrombin; PTT, partial thromboplastin time; SD, standard deviation;
WBC, white blood cell count.
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and acetylsalicylic acid were paused.
Analysis of biochemical safety data revealed no differ-
ences between both groups, with the exception of a
slight increase of creatinine in patients receiving TXA
immediately after surgery (1.2 mg/dL ± 0.8 versus 1.1
mg/dL ± 0.7; P =0 . 0 2 ) .T h eP Tr a t i oa n dP T Tw e r e
Table 3 Biochemical data of patients receiving aprotinin
and tranexamic acid
Aprotinin Tranexamic
acid
Mean SD Mean SD P
Creatinine after surgery (mg/
dL)
All patients 1.1 0.7 1.2 0.8 0.02
Open-heart procedures 1.08 0.50 1.30 0.73 <
0.01
Creatinine POD 1 (mg/dL)
All patients 1.5 5.3 2.2 14.0 0.29
Open-heart procedures 1.37 1.83 1.42 0.65 0.77
CK after surgery (U/mL)
All patients 521 635 474 782 0.33
Open-heart procedures 521 605 589 1307 0.53
CK-MB after surgery (U/mL)
All patients 59 64 54 69 0.27
Open-heart procedures 59 64 77 109 0.39
CK POD 1 (U/mL)
All patients 1013 1496 878 1131 0.16
Open-heart procedures 1032 1462 914 1224 0.48
CK-MB POD 1 (U/mL)
All patients 55 69 52 80 0.51
Open-heart procedures 59 64 67 103 0.42
WBC after surgery (/nL)
All patients 12.6 5.5 12.5 5.4 0.80
Open-heart procedures 13.6 5.7 13.8 6.3 0.74
WBC POD 1 (/nL)
All patients 14.0 4.4 13.8 6.9 0.63
Open-heart procedures 14.4 4.4 13.4 4.2 0.04
Hemoglobin after surgery (g/
dL)
All patients 10.2 1.2 10.5 7.3 0.27
Open-heart procedures 10.1 1.4 11.1 12.9 0.26
Hemoglobin POD 1 (g/dL)
All patients 10.4 1.2 10.3 3.8 0.77
Open-heart procedures 10.3 1.1 10.7 6.6 0.44
Platelets after surgery (/nL)
All patients 144 50 153 56 0.01
Open-heart procedures 143 55 149 62 0.35
Platelets POD 1 (/nL)
All patients 158 55 160 57 0.53
Open-heart procedures 147 59 145 59 0.75
PT ratio after surgery (%)
All patients 65 10 64 10 0.03
Open-heart procedures 64 11 61 10 <
0.01
PT ratio POD 1 (%)
All patients 75 12 74 11 0.04
Open-heart procedures 73 13 71 13 0.12
aPTT after surgery (s)
All patients 51.0 16.7 41.0 14.5 <
0.01
Table 2 Surgical, ICU, and outcome data of patients
receiving aprotinin and tranexamic acid
Aprotinin Tranexamic
acid
CABG n 349 231
% in group 63.1% 69.0%
Valve n 106 48
% in group 19.2% 14.3%
Double valve n 11 2
% in group 2.0% 0.6%
CABG plus valve n 68 41
% in group 12.3% 12.2%
Other n 19 13
% in group 3.4% 3.9%
Mean SD Mean SD P
Duration of surgery (min)
All patients 206 60 211 71 0.28
Open-heart procedures 210 65 235 79 < 0.01
CPB time (min)
All patients 89 42 88 46 0.79
Open-heart procedures 104 47 114 53 0.07
Cross-clamp time (min)
All patients 59 34 57 36 0.37
Open-heart procedures 77 40 85 43 0.08
Euroscore II
All patients 6.3 3.9 5.8 3.7 0.08
Open-heart procedures 7.7 3.6 7.3 3.7 0.42
ICU treatment (days)
All patients 3.1 9.5 3.5 8.1 0.51
Open-heart procedures 4.3 13.8 5.7 11.8 0.38
Hospital stay (days)
All patients 17.0 17.1 18.9 18.6 0.11
Open-heart procedures 20.8 20.8 23.6 25.1 0.28
Mechanical ventilation (h)
All patients 25.6 128.0 45.4 187.3 0.06
Open-heart procedures 36.3 188.4 83.0 263.6 0.07
APACHE II (admission ICU)
All patients 19.4 6.8 19.3 7.0 0.89
Open-heart procedures 20.2 7.3 19.8 6.7 0.60
SAPS II (admission ICU)
All patients 34.3 12.4 36.4 12.5 0.02
Open-heart procedures 36.7 13.0 39.7 13.1 0.06
APACHE II, acute physiology and chronic health evaluation score II; CABG,
coronary artery bypass graft; CPB, cardiopulmonary bypass; ICU, intensive care
unit; SAPS, simplified acute physiological score; SD, standard deviation.
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Page 5 of 14slightly different between both groups (Table 3). Acute
renal failure was identical between groups (9.4% aproti-
nin versus 11.6% TXA, P = 0.31). However, acute renal
failure was seen more often in patients receiving TXA
(13.7%) compared with patients receiving aprotinin
(8.5%; P = 0.02).
Patients receiving aprotinin had a higher rate of late
events of ischemic stroke (3.4% versus 0.9%; P = 0.02)
and late neurologic disability (5.8% versus 2.4%;
P = 0.02). The rate of postoperative convulsive seizures
in the ICU was increased in tendency in patients receiv-
ing TXA (2.7% versus 0.9%; P = 0.05) compared with
patients receiving aprotinin. No difference regarding
myocardial infarction, intracerebral hemorrhage, and
acute renal failure was observed (Table 4). In-hospital
mortality in all patients did not differ between both
groups (6.9% aprotinin versus 8.7% TXA; P = 0.34).
Patients in the TXA group showed a trend for pro-
longed need of mechanical ventilation (45.4 h ± 187.3
versus 25.6 h ± 128.0; P = 0.06. This led in tendency to
a prolonged hospital stay of 2 days compared with the
aprotinin group (18.9 days ± 18.6 versus 17.0 days ±
17.1; P = 0.11) (Table 2).
Patients being treated with TXA had increased cumu-
lative drainage losses at 6, 24, and 48 h after surgery
(Figure 2a; Table 5) compared with patients receiving
aprotinin (Pgroups <0 . 0 1 ;Ptime <0 . 0 1 ;Pintact < 0.01).
These patients did receive significantly more packed red
cells, units of fresh frozen plasma, and platelet concen-
trates (Table 5) compared with patients receiving aproti-
nin. The use of aprotinin was associated with a
decreased risk of being transfused with packed red cells
(P < 0.01), units of fresh frozen plasma (P < 0.01), and
platelet concentrates (P < 0.01) (Figure 3a). Further-
more, the use of TXA was associated with an increased
rate of repeated thoracotomy for bleeding (6.9% versus
2.4%; P < 0.01).
Subgroup with open-heart procedures
In the subgroup of patients undergoing open-heart pro-
cedures, 320 patients (105 receiving TXA and 215
receiving aprotinin) were analyzed. In this group,
patients receiving TXA had significantly higher preo-
perative creatinine (1.31 ± 1.03 mg/dL versus 1.14 ±
0.46 mg/dL; P = 0.04) and again significantly lower
levels of hemoglobin (12.5 ± 1.8 mg/dL versus 13.2 ±
1.9 mg/dL; P > 0.01).
Patients with open-heart procedures receiving TXA
had increased duration of surgery (235 min ± 79 versus
210 min ± 65; P > 0.01); however, no difference between
duration of CPB and aortic cross-clamping time and no
difference between EURO score, APACHE II, and SAPS
score on admission to the ICU was detectable (Table 2).
T h et y p eo fs u r g e r y ,t y p ea n dd u r a t i o no ft r e a t m e n t
with vitamin K antagonists, clopidogrel and aspirin, as
well as other comorbidities did not differ between both
groups.
Patients with open-heart procedures in the TXA
group showed a trend for prolonged need of mechanical
ventilation (83.0 h ± 263.6 versus 36.3 h ± 188.4; P =
0.07. However, in this subgroup, no significant differ-
ence regarding duration of ICU treatment and hospital
stay was detectable (Table 2).
Analysis of biochemical safety data is shown in
Table 3. In this subgroup, an increase of creatinine in
patients receiving TXA immediately after surgery was
seen (1.30 mg/dL ± 0.73 versus 1.08 mg/dL ± 0.50;
P < 0.01). The WBC, PT ratio, and aPTT were slightly
different between both groups (Table 3). Acute renal
failure was identical between groups (9.8% aprotinin ver-
sus 13.3% TXA; P = 0.35). However, acute renal failure
was seen more often in patients receiving TXA (20.0%)
compared with patients receiving aprotinin (11.2%;
P = 0.04).
Even if patients with open-heart procedures receiving
aprotinin did not show a significant higher rate of
events of ischemic stroke (4.2% versus 1.0%; P =0 . 1 2 ) ,
we detected a higher rate of late neurologic disability
(7.0% versus 1.0%; P = 0.03). The rate of postoperative
convulsive seizures was increased in patients receiving
TXA (6.7% versus 1.9%; P = 0.04) compared with
patients treated with aprotinin. No difference regarding
intracerebral hemorrhage and acute renal failure was
observed. A slight increase in the rate of myocardial
infarction was seen in patients receiving TXA (Table 4).
Notably, in patients with open-heart procedures, in-
hospital mortality was more than twofold increased in
patients receiving TXA (16.2% TXA versus 7.5% aproti-
nin; P = 0.02). The leading cause of death was
Table 3 Biochemical data of patients receiving aprotinin
and tranexamic acid (Continued)
Open-heart procedures 53.6 19.0 43.4 21.0 <
0.01
aPTT POD 1 (s)
All patients 44.0 15.1 41.2 10.3 <
0.01
Open-heart procedures 46.6 17.9 42.7 12.2 0.05
AT III after surgery (%)
All patients 67 12 68 13 0.37
Open-heart procedures 69 12 69 15 0.67
AT III POD 1 (%)
All patients 76 14 74 14 0.31
Open-heart procedures 78 13 75 15 0.34
AT III, antithrombin; CK, creatinine kinase; CK-MB, creatinine kinase isoenzyme
MB; POD, postoperative day; PT, prothrombin ratio; PTT, partial
thromboplastin time; SD, standard deviation; WBC, white blood cell count.
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Aprotinin Tranexamic acid P
Myocardial infarction (ICU) All patients N 8 6 0.78
Open-heart procedures 0 2 0.04
All patients % in group 1.4% 1.8%
Open-heart procedures 0.0% 1.9%
Myocardial infarction (late) All patients N 7 5 0.77
Open-heart procedures 1 1 0.60
All patients % in group 1.3% 1.5%
Open-heart procedures 0.5% 1.0%
Seizures (ICU) All patients N 5 9 0.05
Open-heart procedures 4 7 0.04
All patients % in group 0.9% 2.7%
Open-heart procedures 1.9% 6.7%
Seizures (late) All patients N 6 1 0.20
Open-heart procedures 3 1 0.74
All patients % in group 1.1% 0.3%
Open-heart procedures 1.4% 1.0%
Ischemic stroke (ICU) All patients N 21 9 0.45
Open-heart procedures 10 6 0.68
All patients % in group 3.8% 2.7%
Open-heart procedures 4.7% 5.7%
Ischemic stroke (late) All patients N 19 3 0.02
Open-heart procedures 9 1 0.12
All patients % in group 3.4% 0.9%
Open-heart procedures 4.2% 1.0%
Neurologic disability (ICU) All patients N 21 11 0.85
Open-heart procedures 12 9 0.34
All patients % in group 3.8% 3.3%
Open-heart procedures 5.6% 8.6%
Neurologic disability (late) All patients N 32 8 0.02
Open-heart procedures 15 1 0.03
All patients % in group 5.8% 2.4%
Open-heart procedures 7.0% 1.0%
Intracerebral hemorrhage (ICU) All patients N 3 1 1.00
Open-heart procedures 2 1 1.00
All patients % in group 0.5% 0.3%
Open-heart procedures 0.9% 1.0%
Intracerebral hemorrhage (late) All patients N 1 0 1.00
Open-heart procedures 0 0 n/a
All patients % in group 0.2% 0.0%
Open-heart procedures 0.0% 0.0%
Mortality (in-hospital) All patients N 38 29 0.34
Open-heart procedures 16 17 0.02
All patients % in group 6.9% 8.7%
Open-heart procedures 7.5% 16.2%
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Page 7 of 14Figure 2 Cumulative blood loss for the first 48 h after surgery for (a) all patients and (b) patients undergoing open-chamber procedures.
(a) All patients (Pgroups <0 . 0 1 ;Ptime < 0.01; Pintact <0 . 0 1 ) .(b) Patients with open-heart procedures (Pgroups <0 . 0 1 ;Ptime < 0.01; Pintact <0 . 0 1 ) .
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Page 8 of 14thromboembolic events (21 of 38 deaths) in patients
receiving TXA compared with the aprotinin group (11
of 29 deaths). In the multivariate backward stepwise
logistic regression, aprotinin as antifibrinolytic, higher
EURO score II, and prolonged CPB time were identified
as independent risk factors for the excess mortality in
the open-heart procedures group (Table 6).
With regard to the efficacy of antifibrinolytic therapy,
open-heart procedures being treated with TXA showed
increased cumulative drainage losses at 6, 24, and 48 h
after surgery (Figure 2b; Table 5) compared with
patients receiving aprotinin (Pgroups <0 . 0 1 ;Ptime <0 . 0 1 ;
Pintact < 0.01) and did receive significantly more packed
red blood cells (PRBCs), units of fresh frozen plasma
(FFP), and platelet concentrates (PCs) (Figure 3b).
Again, the aprotinin patients had a decreased risk of
being transfused with PRBCs (P < 0.01), units of FFP (P
<0 . 0 1 ) ,a n dP C( P < 0.01) (Figure 3b; Table 5). The
need for repeated thoracotomy for bleeding in patients
receiving TXA was almost 5 times higher (14.3% versus
3.3%; P < 0.01) compared with aprotinin-treated patients
(Table 5).
Discussion
The two major findings of our study are as follows: first,
in the overall cardiac surgery population studied, the
administration of high-dose TXA showed a strong trend
toward an association with convulsive seizures, whereas
aprotinin was associated with a higher rate of stroke
and neurologic disability after cardiac surgery with CPB.
Second, in patients undergoing open-heart cardiac sur-
gery treated with TXA, an increased mortality and a sig-
nificant increase in convulsive seizures compared with
patients receiving aprotinin was observed.
At our institution, aprotinin has been used for many
years as the primary antifibrinolytic in patients under-
going cardiac surgery with CPB. Several studies and
meta-analyses showed its superiority compared with
other antifibrinolytic drugs, especially in high-risk
patients undergoing cardiac surgery [8,12-14]. However,
Table 5 Blood loss, transfusion, and coagulation-related
data for patients receiving aprotinin and tranexamic acid
Aprotinin Tranexamic
acid
Mean SD Mean SD P
Blood loss first 6 h (mL)
All patients 230 338 366 492 < 0.01
Open-heart procedures 229 260 459 616 < 0.01
Blood loss first 24 h (mL)
All patients 437 669 613 705 < 0.01
Open-heart procedures 431 431 707 881 < 0.01
Blood loss 48 h (mL)
All patients 72 159 118 223 < 0.01
Open-heart procedures 77 177 137 284 0.02
Packed red blood surgery
(units)
All patients 0.5 1.2 0.7 1.5 0.02
Open-heart procedures 0.6 1.2 0.8 1.4 0.19
Packed red blood first 24
h (units)
All patients 0.7 2.1 1.3 2.4 < 0.01
Open-heart procedures 0.8 1.8 1.9 2.9 < 0.01
FFP surgery (units)
All patients 0.3 1.1 0.4 1.4 0.09
Open-heart procedures 0.5 1.5 0.8 1.6 0.13
FFP first 24 h (units)
All patients 0.8 4.4 1.6 5.0 < 0.01
Open-heart procedures 1.0 3.2 2.8 7.3 < 0.01
Platelet concentrates
surgery (units)
All patients 0.1 0.5 0.2 0.6 < 0.01
Open-heart procedures 0.1 0.5 0.3 0.7 < 0.01
Platelet concentrates first
24 h (units)
All patients 0.2 0.8 0.4 1.2 < 0.01
Open-heart procedures 0.2 0.9 0.6 1.7 < 0.01
PPSB (IU)
All patients 14.1 154.7 30.4 186.1 0.16
Open-heart procedures 19.5 168.0 57.1 269.9 0.13
AT III (IU)
All patients 23.5 200.5 41.8 275.8 0.26
Open-heart procedures 30.2 237.3 38.1 237.1 0.78
F XIII (IU)
All patients 9.0 130.0 14.2 161.8 0.60
Open-heart procedures 11.6 120.3 23.8 244.0 0.55
aFVII (IU)
All patients 3.1 46.8 5.0 39.1 0.52
Open-heart procedures 3.4 36.8 13.7 65.1 0.07
Desmopressin (μg/kg)
All patients 0.3 2.4 0.2 1.9 0.58
Open-heart procedures 0.5 3.2 0.4 2.5 0.71
Rethoracotomy
(bleeding)
All patients N 13 23 < 0.01
Table 5 Blood loss, transfusion, and coagulation-related
data for patients receiving aprotinin and tranexamic acid
(Continued)
Open-heart
procedures
7 15 < 0.01
All patients % in
group
2.4% 6.9%
Open-heart
procedures
3.3% 14.3%
aFVII, activated factor VII concentrate; AT III, antithrombin; FFP, fresh frozen
plasma; F XIII, factor XIII concentrate; ICU, intensive care unit; PPSB,
coagulation factor concentrate (prothrombin, factor VII, factor X, factor IX); OR,
odds ratio; SD, standard deviation.
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Page 9 of 14Figure 3 Percentage of patients receiving transfusions for all patients and for patients undergoing open chamber procedures. (a) All
patients (Pgroups < 0.01; Ptime < 0.01; Pintact < 0.01). (b) Patients with open-heart procedures (Pgroups < 0.01; Ptime < 0.01; Pintact < 0.01).
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was not thoroughly investigated [1-3]. Early reports
linked its use with a higher incidence of graft occlusion
after CABG surgery and renal failure [15,16]. Recently
the use of aprotinin was associated with a significantly
increased risk for renal failure, myocardial ischemia,
stroke [1], and an impaired 5-year mortality [2]. In com-
parison, the same studies suggested TXA to be the safer
choice of antifibrinolytic treatment. So far, only a few
studies and case reports have reported the safety profile
of TXA [3,17].
Our results support an association between convulsive
seizures and the use of TXA, and especially patients
undergoing open-heart procedures seem to be at risk.
This supports recent data from the literature indicating
an increased rate of seizures in patients receiving TXA
for open-heart surgery (7.9% compared with 1.2% (P <
0.01) compared with aprotinin-treated patients) [7]. Ear-
lier case reports and experimental data indicated that
TXA is linked to an epileptogenic effect if it is applied
to the central nervous system [18-20]. It was hypothe-
sized that this effect might occur in part because of
binding of TXA to the g-aminobutyric acid (GABA)
binding site of GABA-(A) receptors, as shown in mem-
branes from rat cerebral cortex [21]. A recent report of
Murkin et al. [9] linked the use of TXA to seizures. In
two separate centers, they observed a notable increase
in the incidence of postoperative convulsive seizures
from 1.3% to 3.8% in patients having undergone major
cardiac surgical procedures. These events were tempo-
rally coincident with the introduction of high-dose TXA
therapy after discontinuation of aprotinin from general
clinical use. They concluded that use of high-dose TXA
in older patients in conjunction with cardiopulmonary
bypass and open-heart cardiac surgery is associated with
clinical seizures in susceptible patients [9].
Furthermore, we could show an association between
renal failure and treatment with TXA. This could be an
effect of the increased blood loss, need for transfusion,
and need of repeated thoracotomy. All these factors
have been linked to unfavorable outcomes in cardiac
surgery patients [22,23]. Conversely, this finding is sur-
prising, as the use of TXA was associated with a better
renal outcome in previous studies [1,3].
Our findings that patients receiving aprotinin had a
more than threefold higher rate of ischemic stroke and
neurologic disability are in line with those of previous
studies [1]. One hypothesis for explanation of the
impaired neurologic outcome with aprotinin may be the
occurrence of microvascular thrombosis, as described by
Sundt et al. [24], who reported platelet-fibrin thrombi
among multiple vessels, including the cerebral arteries,
on postmortem examination of patients who had
received aprotinin. These results confirm earlier results
Table 6 Multivariate backward stepwise logistic regression analysis of the increased mortality in open-heart
procedures
B SE Sig. Odds ratio (OR) 95.0% CI for OR
Lower Upper
Step 1 Age -0.043 0.018 0.019 0.958 0.924 0.993
CPB time 0.012 0.004 0.002 1.012 1.004 1.020
EURO Score II 0.278 0.063 0.000 1.321 1.168 1.493
Creatinine preop 0.146 0.207 0.481 1.157 0.772 1.734
Hemoglobin preop -0.148 0.125 0.238 0.863 0.675 1.103
Antifibrinolytic -0.788 0.437 0.071 0.455 0.193 1.070
Constant -0.940 1.959 0.631 0.391
Step 2 Age -0.041 0.018 0.023 0.959 0.926 0.994
CPB time 0.012 0.004 0.001 1.012 1.005 1.020
EURO Score II 0.276 0.062 0.000 1.318 1.167 1.489
Hemoglobin preop -0.175 0.119 0.142 0.840 0.665 1.060
Antifibrinolytic -0.832 0.431 0.054 0.435 0.187 1.013
Constant -0.534 1.866 0.775 0.586
Step 3 Age -0.044 0.018 0.014 0.957 0.923 0.991
CPB Time 0.011 0.004 0.003 1.011 1.004 1.019
EURO Score II 0.300 0.060 0.000 1.350 1.200 1.518
Antifibrinolytic -0.947 0.424 0.025 0.388 0.169 0.890
Constant -2.554 1.302 0.050 0.078
CI, confidence interval; CPB, cardiopulmonary bypass; OR, odds ratio; SD, standard deviation; SEM, standard error of the mean.
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but are in contrast with results that report no difference
in the incidence of stroke for aprotinin in cardiac sur-
gery [3,10,25]. This might well be explained by the fact
that the rates of ischemic stroke in the TXA group were
low. Another German center reported a stroke rate for
open procedures of 7.4% [26]. The McSPI dataset sug-
gests that patients having combined CABG/valve repla-
cement had permanent neurologic deficit in about 8%
[27]. Therefore, the observed neurologic deficit rate for
aprotinin might be about as expected.
However, also for TXA, an association with a throm-
boembolic risk must be hypothesized, as the leading
cause of death in the group of patients treated with
TXA was thromboembolic.
Our result that patients treated with TXA had
increased cumulative drainage loss compared with
patients receiving aprotinin is in accordance with pre-
vious studies and meta-analysis [8,12-14,28,29]. It has
been shown that aprotinin is superior to TXA in redu-
cing postoperative blood loss. One explanation for this
may be its potential to inhibit plasmin, the final enzyme
of fibrinolysis [30]. Our results confirm that the total
number of transfusions and the risk of being transfused
were significantly lower in the aprotinin group, as
shown by others [14]. The increased bleeding might be
responsible for the longer duration of surgery to achieve
surgical hemostasis. Furthermore, the increased blood
loss could explain in part the somewhat prolonged ven-
tilation and the trend for prolonged hospital stay in
patients receiving TXA.
The increased bleeding seen in our patients receiving
TXA explains the significantly higher rate of patients
transfused with PRBC, FFP, and PC. This was observed
in the general patient population and was even more
pronounced in patients with open-heart procedures.
More than two thirds of patients undergoing open-heart
procedures in the TXA group received allogenic PRBC
transfusion. In line with this finding is the significantly
increased rate of repeated thoracotomies in the TXA
group. As bleeding and reoperation for bleeding has a
major impact on outcome, this increased bleeding and
need for transfusion, as well as the increased rate for
reoperation seen in TXA patients, might in part be also
responsible for the increased mortality seen in the TXA
open-heart procedures subgroup [23].
The results of our study are in line with recent data [10]
indicating that, compared with TXA, the safety profile of
aprotinin is better in high-risk cardiac surgery patients. It
seems that increased bleeding is associated with a higher
risk of complications and mortality after cardiac surgery
[23]. Although the effect of aprotinin on mortality is still
considered controversial [6,7], an increased mortality
might be found in high-risk patients treated with TXA
compared with aprotinin-treated patients [10]. These
results might indicate a beneficial risk/benefit profile for
aprotinin in certain high-risk patients, like those with
open-heart procedures analyzed in our study [10].
The strengths of our study include the clinically real-
world, unselected nature of the patient population and
the prospective and unbiased data collection of patients
receiving TXA being treated at a single center. Another
strength is that in this study, no crossover between
groups requiring some sort of propensity score match-
ing was possible, as aprotinin is no longer available.
However, obviously, this study also has all methodologic
limitations of a retrospective study with regard to the
aprotinin patients. Nonetheless, as we changed our rou-
tine practice on July 1, 2006, standard operating proce-
dures in regard to treating cardiac surgical patients were
not changed. We had the same surgeons and the same
personnel in our operating rooms, ICUs, IMCUs, and
normal wards, so that supposedly did not influence our
results. As we adhere on a day-by-day basis to written
standard operating procedures, all perioperative proce-
dures (anesthetic management, ICU management, trans-
fusion guidelines, and so on) are extremely standardized.
Unfortunately, it was not possible to include 260
patients undergoing redo surgery, as all of these patients
received aprotinin at that time as part of our standard
operating procedures. Therefore, at this time from our
own data, we cannot comment on whether aprotinin or
tranexamic acid is superior in redo surgery. Although all
the deaths were clinically adjudicated in our trial, with-
out detailed investigations like invasive diagnostic or
autopsies, a potential source of error remains.
Conclusions
The association between higher mortality and the minor
efficiency of TXA questions the routine administration
of high-dose TXA in cardiac surgery. In particular, our
finding of the more than twofold increased mortality in
patients undergoing open-heart procedures receiving
tranexamic acid is worrying. However, our results con-
firm also that aprotinin is associated with severe neuro-
l o g i ca d v e r s er e a c t i o n s .T h es a f e t yp r o f i l eo f
antifibrinolytic treatment–aprotinin and TXA–warrants
f u r t h e re v a l u a t i o nt oa n s w e rt h eq u e s t i o nw h e t h e rt h e
benefit of this treatment outweighs its potential risks.
For the future, controlled trials investigating the safety
profile of antifibrinolytic therapy are needed. With
regard to TXA, the effective and safe dosage as well as
the patients who will most likely benefit from this medi-
cation must be established.
Key messages
￿ The association between higher mortality and the
minor efficiency of tranexamic acid questions the
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Page 12 of 14routine administration of high-dose tranexamic acid
in cardiac surgery. In particular, our finding of the
more than twofold increased mortality in patients
undergoing open-heart procedures receiving tranexa-
mic acid is worrying.
￿ Aprotinin and tranexamic acid were associated
with neurologic adverse react i o n si nt h i sr e t r o s p e c -
tive study.
￿ The safety profile of antifibrinolytic treatment–
aprotinin and tranexamic acid–warrants further eva-
luation to answer the question whether the benefit
of this treatment outweighs its potential risks.
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